Guilherme Nader Marta: CLEOPATRA trial analysis shows that complete response at first imaging re-evaluation correlates with longer PFS and OS

Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn:

“Many patients with HER2-positive breast cancer have long-term response to trastuzumab-pertuzumab that is >16% with no evidence of progression at 8 years in the CLEOPATRA trial

In this analysis led by Véronique Debien we show that complete response at first imaging re-evaluation correlates with longer PFS and OS.”

Source: Guilherme Nader Marta/LinkedIn